Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

NCT04699461 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.

NCT NCT04699461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04699461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)
Lead sponsor
ADC Therapeutics S.A.
Phase
Phase 2
Overall status
Terminated
Start date
November 4, 2021
Completion date
November 25, 2022
Enrollment
6 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

refractory follicular lymphoma, relapsed follicular lymphoma